Aldosterone antagonists inhibit the release of inflammatory factors and renal fibrosis by blocking mineralocorticoid receptors, yet they also pose a risk of hyperkalemia and an increased likelihood of acute kidney injury when used in combination with angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers (Chung et al. 2020). The gene discussed is NR3C2; the disease is Hyperkalemia.